Aller au contenu principal
Accès ouvert déclaré 2021 article

Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

24Citations signalées, ce qui n’est pas une note de qualité
118Institutions déclarées
19Pays d’affiliation déclarés

Rattachement africain : nl, au, us, ca, de, se, dk, gb, it, es, fr, fi, pl, be, no, gr, cy, mk, il. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Given the high heterogeneity among breast tumors, associations between common germline genetic variants and survival that may exist within specific subgroups could go undetected in an unstratified set of breast cancer patients. METHODS: We performed genome-wide association analyses within 15 subgroups of breast cancer patients based on prognostic factors, including hormone receptors, tumor grade, age, and type of systemic treatment. Analyses were based on 91,686 female patients of European ancestry from the Breast Cancer Association Consortium, including 7531 breast cancer-specific deaths over a median follow-up of 8.1 years. Cox regression was used to assess associations of common germline variants with 15-year and 5-year breast cancer-specific survival. We assessed the probability of these associations being true positives via the Bayesian false discovery probability (BFDP < 0.15). RESULTS: Evidence of associations with breast cancer-specific survival was observed in three patient subgroups, with variant rs5934618 in patients with grade 3 tumors (15-year-hazard ratio (HR) [95% confidence interval (CI)] 1.32 [1.20, 1.45], P = 1.4E-08, BFDP = 0.01, per G allele); variant rs4679741 in patients with ER-positive tumors treated with endocrine therapy (15-year-HR [95% CI] 1.18 [1.11, 1.26], P = 1.6E-07, BFDP = 0.09, per G allele); variants rs1106333 (15-year-HR [95% CI] 1.68 [1.39,2.03], P = 5.6E-08, BFDP = 0.12, per A allele) and rs78754389 (5-year-HR [95% CI] 1.79 [1.46,2.20], P = 1.7E-08, BFDP = 0.07, per A allele), in patients with ER-negative tumors treated with chemotherapy. CONCLUSIONS: We found evidence of four loci associated with breast cancer-specific survival within three patient subgroups. There was limited evidence for the existence of associations in other patient subgroups. However, the power for many subgroups is limited due to the low number of events. Even so, our results suggest that the impact of common germline genetic variants on breast cancer-specific survival might be limited.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
Date Crossref
18/08/2021
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

The Netherlands Cancer InstituteQIMR Berghofer Medical Research InstituteNational Institutes of HealthNational Cancer InstituteMount Sinai HospitalUniversity of TorontoLunenfeld-Tanenbaum Research InstituteUniversity of California, IrvineGerman Cancer Research CenterHeidelberg UniversityFred Hutch Cancer CenterUniversity of Wisconsin–MilwaukeeLund UniversityUniversität HamburgUniversity Medical Center Hamburg-EppendorfUniversitätsklinikum ErlangenComprehensive Cancer Center ErlangenUniversity of CopenhagenCopenhagen University HospitalGentofte HospitalUniversity of CambridgeNational Center for Tumor DiseasesDeutsches Konsortium für Translationale KrebsforschungInstitute for Prevention and Occupational MedicineHuntsman Cancer InstituteKaiser PermanenteUniversity of PisaServicio Gallego de SaludUniversity Cancer Center HamburgRoswell Park Comprehensive Cancer CenterThe University of SydneyWestmead Institute for Medical ResearchFriedrich-Alexander-Universität Erlangen-NürnbergMayo Clinic in ArizonaUniversity of SheffieldKarolinska InstitutetFox Chase Cancer CenterMedizinische Hochschule HannoverCentre international de recherche sur le cancerUniversity of WestminsterUniversity of SouthamptonBrigham and Women's HospitalHarvard UniversityManchester Academic Health Science CentreUniversity of ManchesterUniversity of California, Los AngelesManchester University NHS Foundation TrustSt Mary's HospitalCurtin UniversityFundación Pública Galega de Medicina XenómicaHospital Clínico San CarlosUniversity of California San DiegoInstituto de Investigación Sanitaria del Hospital Clínico San CarlosCentro de Investigación Biomédica en Red de CáncerCancer Council VictoriaThe University of MelbourneOulu University HospitalMonash HealthMonash UniversityUniversity of OuluInsermCentre de recherche en Epidémiologie et Santé des PopulationsUniversity of CologneHelmholtz MunichUniversity Hospital CologneGerman Center for Diabetes ResearchUniversity of Southern CaliforniaStockholm South General HospitalMayo Clinic in FloridaUniversity of Eastern FinlandErasmus MC Cancer InstituteDr. Margarete Fischer-Bosch-Institute of Clinical PharmacologyUniversity of TübingenCancer Research UK Manchester InstituteUniversity of OxfordPomeranian Medical UniversityUniversity Hospital UlmStanford UniversityKU LeuvenDivision of Cancer Epidemiology and GeneticsOslo University HospitalUniversity of OsloCity of HopeVIB-KU Leuven Center for Cancer BiologyUniversity of Hawaiʻi at MānoaUniversity of Hawaii SystemCancer Center of HawaiiUniversity of Hawaii Cancer CenterKarolinska University HospitalKuopio University HospitalUniversity Hospital of HeraklionCyprus Institute of Neurology and GeneticsUniversity of HelsinkiHelsinki University HospitalUniversity Health NetworkUniversity of North Carolina at Chapel HillQueen's University BelfastAmerican Cancer SocietyFondazione IRCCS Istituto Nazionale dei TumoriIFOMMacedonian Academy of Sciences and ArtsCarmel Medical CenterHospital Universitario Puerta de Hierro MajadahondaUniversity Hospital of LarissaKing's College LondonUniversity Hospital HeidelbergSs. Cyril and Methodius University in SkopjeThe University of Western AustraliaInstitute of Cancer ResearchCornell UniversityWeill Cornell MedicineColumbia UniversityLeiden University Medical CenterUniversity of BirminghamCentre for Human GeneticsUppsala UniversityNordLabNetherlands Cancer Institute-Antoni van Leeuwenhoek Hospital

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

BRCA gene mutations in cancerGenetic Associations and EpidemiologyBreast Cancer Treatment Studies

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.